GHK-Cu
Copper tripeptide studied in dermatology for skin remodeling and wound contexts. Topical formulations are widely used in cosmetics.
Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.
What the research shows
Topical GHK-Cu has dermatology RCTs supporting effects on collagen, skin barrier, and post-procedure recovery. Reasonable mechanistic data for fibroblast and keratinocyte effects.
What's still experimental
Injectable use in humans is largely unproven. Hair-loss and systemic anti-aging claims need larger trials.
Anecdotal / community reports
Cosmetic skin and hair-thickness reports are widespread; topical formulations are widely available OTC.
Anecdotal reports are NOT scientific evidence. They reflect personal experience and may not generalize.
FDA approval status
Source: openFDA + DailyMed (NIH/NLM)Doses studied in research
No established dose rangeWhat published trials tested or FDA-approved labels specify. Reporting research facts — not a SmartPeptide recommendation.
This is the honest answer for peptides like BPC-157, IGF-1 LR3, MOTS-c, Epitalon and similar research compounds — robust human dose- ranging studies have not been published. Always work with a licensed clinician familiar with experimental peptides if you are considering any use.
FDA enforcement & recalls
Live · openFDA Drug Enforcement API- Class IIOngoing· Voluntary: Firm initiatedFDA record
GHK-Cu (Copper Peptide) for Injection, all strengths and presentations, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692.
Reason: Lack of Assurance of Sterility
Jul 30, 2025·GenoGenix LLC - Class IIOngoing· Voluntary: Firm initiatedFDA record
GHK-CU, 10 MG/ML, 5 ML vial, The Guyer Institute of Molecular Medicine, Indianapolis, IN
Reason: Lack of Assurance of Sterility: due to concerns with production processes which cannot assure sterility of products intended to be sterile.
Nov 30, 2020·Advanced Nutriceuticals, LLC
Mechanism & targets
ChEMBL · UniProt · Open TargetsMolecule (ChEMBL)
View on ChEMBL- UnknownDiagnostic agent
Live research
PubMed · ClinicalTrials.gov · Europe PMC · OpenAlexRecent PubMed studies
- Microenvironment-responsive injectable dynamic hydrogel for sequential antioxidant and tissue regeneration therapy of radiation-induced skin injury.Yu X, Yang T, Bei Z, et al. · Bioactive materials · 2026 Sep
- Copper peptide activated cascade catalysis for glucose regulation and hypoxia reversing in infected diabetic wound healing.Huang ZJ, Huang RF, Jiao PP, et al. · Materials today. Bio · 2026 Aug
- Hierarchical regulation and mechanism of "open-hollow-fibrous network" structures: Osteogenic-angiogenic coupling responses of poly(γ-benzyl-L-glutamate) microspheres.Su J, Zhang Y, Cao Y, et al. · Biomaterials advances · 2026 Jun 15
- Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs.Mazzola J, Rosenfeld M, Tucker M, et al. · Research square · 2026 May 26
- Glycyl-L-histidyl-L-lysine-Cu2(+) (GHK-Cu) Attenuates CuSO(4) or LPS induced-inflammation in Zebrafish larvae model.Hu J, Zhang C, Wang F, et al. · European journal of pharmacology · 2026 May 10
- The GHK-Cu delays aging in Caenorhabditis elegans via coordinated regulation of mitochondrial function and activation of DAF-16/SKN-1 pathways.Wen H, Zhao K, Luo X, et al. · Biogerontology · 2026 May 5
Clinical trials (ClinicalTrials.gov)
- Topical GHK-Cu Gel for Acute Skin Wound HealingRECRUITINGNCT07437586 · PHASE2 · n=60 · 2026-02-02
- Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types.COMPLETEDNCT05932732 · PHASE4 · n=27 · 2023-11-20
Europe PMC — 347 additional records
Includes EU/UK studies and PubMed Central full-text articles. Often surfaces research weeks before PubMed indexes it.
- Microenvironment-responsive injectable dynamic hydrogel for sequential antioxidant and tissue regeneration therapy of radiation-induced skin injuryYu X, Yang T, Bei Z, et al. · 2026Open access
- Copper peptide activated cascade catalysis for glucose regulation and hypoxia reversing in infected diabetic wound healingHuang ZJ, Huang RF, Jiao PP, et al. · 2026
- Decoding Hyperpigmentation from Biological Mechanisms to Actives with Clinically Proven Topical Efficacy: A Narrative ReviewDuval C, Qiu J, Warrick E, et al. · 2026Open access
- Injuries, Injections, and Internet Forums: A Qualitative Study of Reddit User Perspectives on Peptide Therapy After Orthopaedic SurgeryRosenberg AE, Taylor B, Rasquinha RD, et al. · 2026
Research volume (OpenAlex topic graph)
Human clinical evidence
Semantic Scholar · AI TLDRs · influence-rankedMost influential human studies
- Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene DataReviewOpen access6 influential / 126 citedL. Pickart, A. Margolina · International Journal of Molecular Sciences · 2018
TLDR GHK has been found to possess powerful cell protective actions, such as multiple anti-cancer activities and anti-inflammatory actions, lung protection and restoration of chronic obstructive pulmonary disease (COPD) fibroblasts, suppression of molecules thought to accelerate the diseases of aging, and activation of cell cleansing via the proteasome system.
- Modulation of Gene Expression in Human Breast Cancer MCF7 and Prostate Cancer PC3 Cells by the Human Copper-Binding Peptide GHK-Cu.ReviewOpen access1 influential / 2 citedL. Pickart, Factoria Boulevard Se Suite Number Bellevue Wa Usa Skin Biology, A. Margolina, et al. · 2021
TLDR GHK-Cu’s gene effects on MCF7 breast cancer cells and PC3 prostate cancer cells are presented and laboratory evidence supporting GHK's ability to restore tissue integrity and health via multiple mechanisms are reviewed, which can be beneficial for cancer treatment.
- Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic ApplicationJournal articleOpen access2 influential / 26 citedMichał Dymek, Karolina Olechowska, K. Hąc-Wydro · Pharmaceutics · 2023
TLDR The obtained results confirmed that the liposomes can be used as carriers for biomimetic peptides such as copper-binding peptide and that the GHK-Cu did not significantly affect the tyrosinase activity but led to elastase inhibition, thus reducing the rate of elastin degeneration and supporting the structural integrity of the skin.
- Are We Ready to Measure Skin Permeation of Modern Antiaging GHK–Cu Tripeptide Encapsulated in Liposomes?ReviewKarolina Ogórek, Kinga Nowak, Emilia Wadych · Molecules · 2025
TLDR An analysis of the literature data reveals that the transport of liposomes containing GHK–Cu received little attention, which gives an impetus to the methodological developments for assessing the effect of liposomes on GHK–Cu transportation and trafficking.
- BPC-157 and GHK-Cu in Wound Healing and Tissue Repair: A Review of Clinical Efficacy and SafetyReviewOpen accessOlaf Wojcieszuk, Łukasz Starczewski, Adrianna Babik · Quality in Sport · 2026
TLDR BPC-157 and GHK-Cu show therapeutic potential in wound healing, though evidence is largely preclinical, and this review provides groundwork for future research and highlights safety for sports medicine practitioners.
Research funding & verification
NIH RePORTER · CrossRef DOI registryNIH-funded research
U.S. National Institutes of Health- 1U01AG082350-01A1$30.8MADRC Consortium for Clarity in ADRD Research Through ImagingBRADFORD C DICKERSON · UNIVERSITY OF WISCONSIN-MADISON · FY2023
- 5U01AG082350-02$29.6MADRC Consortium for Clarity in ADRD Research Through ImagingSarah Biber · UNIVERSITY OF WISCONSIN-MADISON · FY2024
- 5U01HD052102-15$18.8MPediatric HIV/AIDS Cohort Study (PHACS): Data and Operations Center (DOC).PAIGE L WILLIAMS · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · FY2019
- 5U01HD052102-14$18.3MPediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC) Substudy: Assessment of HPV associated anogenital morbidity in HPV-vaccinated perinatally HIV infected (PHIV) in Adolescent MedGeorge R Seage · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · FY2018
Publication landscape
CrossRef · DOI registry- National Natural Science Foundation of China26,542 works
- National Key Research and Development Program of China3,521 works
- Fundamental Research Funds for the Central Universities2,561 works
- China Postdoctoral Science Foundation1,775 works
- National Research Foundation of Korea1,684 works
- National Science Foundation1,314 works
Funder diversity is a credibility signal. Research concentrated in a single drug company's funding warrants more scrutiny than research funded across NIH, charities, and academic grants.
Preprints — cutting edge
bioRxiv · medRxiv · via Europe PMCPreprints have NOT been peer-reviewed. They are early research shared by authors before formal validation. Treat findings as preliminary.
- PreprintSelf-Assembled Mesoporous Scaffold Enabled Hybrid Hole-Transport Layer for Efficient Perovskite Solar CellsQin P, Ding B, Li Y, et al. · 2026-06-11
- PreprintMiddle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programsMazzola J, Rosenfeld M, Tucker M, et al. · 2026-05-26
- PreprintMiddle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programsMazzola J, Rosenfeld M, Tucker M, et al. · 2026-04-13
- PreprintEvaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured AbundanceMendias CL, Awan TM. · 2026-04-24
- PreprintSafety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic PerformanceMendias CL, Awan TM. · 2026-04-07
- PreprintSafety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic PerformanceMendias CL, Awan TM. · 2025-12-12
Known risks
Topical use is generally well tolerated; injectable use lacks robust safety data.
Reported side effects
Skin irritation in sensitive users.
FDA adverse event reports (FAERS)
Updated quarterly by FDAMost-reported reactions
- Anaphylactic Shock1
- Blood Pressure Decreased1
- Flushing1
- Heart Rate Decreased1
- Hyperhidrosis1
- Hypersensitivity1
- Immobile1
- Loss Of Consciousness1
- Pallor1
- Syncope1
Counts from FDA Adverse Event Reporting System (FAERS). Voluntary reports — they show what was reported, not whether the drug caused the event. Many reports lack confirmation. FAERS docs
What requires medical supervision
Topical use is generally well tolerated. Injectable forms warrant clinical supervision.
Questions for your clinician
- Topical vs injectable — what's the evidence delta for my goal?
- Are there interactions with other dermatologic treatments?